DexCom, Inc. (NASDAQ:DXCM) Receives $98.32 Consensus Price Target from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have received an average recommendation of “Moderate Buy” from the twenty-one analysts that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $98.32.

DXCM has been the topic of several analyst reports. Citigroup reaffirmed a “buy” rating and issued a $102.00 target price (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Mizuho began coverage on DexCom in a report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price target on the stock. Barclays raised their price target on DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a report on Monday, May 5th. Finally, Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares of the company’s stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president now directly owns 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 76,110 shares of company stock valued at $5,586,695 over the last three months. Company insiders own 0.32% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock valued at $3,240,763,000 after purchasing an additional 925,882 shares during the period. Jennison Associates LLC boosted its position in shares of DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after purchasing an additional 2,879,489 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the period. Geode Capital Management LLC boosted its position in shares of DexCom by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock valued at $775,256,000 after purchasing an additional 56,094 shares during the period. Finally, Nuveen LLC acquired a new position in shares of DexCom in the 1st quarter valued at $554,893,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $85.68 on Friday. The business’s fifty day moving average price is $76.73 and its 200 day moving average price is $79.18. DexCom has a 12-month low of $57.52 and a 12-month high of $118.80. The stock has a market capitalization of $33.60 billion, a PE ratio of 59.92, a price-to-earnings-growth ratio of 2.30 and a beta of 1.46. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the business earned $0.32 earnings per share. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. Equities research analysts forecast that DexCom will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.